

**AMENDMENT TO THE CLAIMS**

1-5. (canceled)

6. (currently amended) A method of inducing a B-cell immune response ~~infor protecting~~ a human subject against systemic human parainfluenza virus-1 (hPIV-1) infection comprising administering to the subject via intranasal administration an effective immunizing amount of a composition comprising an unmodified Sendai virus and a pharmaceutically acceptable carrier.

7. (original) The method of claim 6 wherein said composition is administered to the upper respiratory tract.

8. (original) The method of claim 6 wherein said composition is administered in a form selected from the group consisting of a spray, one or more droplets and an aerosol.

9. (original) The method of claim 6 wherein said composition is administered to said subject by a means selected from the group consisting of intranasal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, and administration to mucous membranes.

10. (original) The method of claim 6 wherein said composition elicits an hPIV-1 specific immune response in the group of cells consisting of B-cells or T-cells (CD4+ and/or CD8+ T-cells), or a combination thereof.

11. (canceled)

12. (currently amended) The method of claim ~~6~~<sup>11</sup> wherein said human is less than 10 years old.

13. (original) The method of claim 12 wherein said human is less than 5 years old.

14. (original) The method of claim 13 wherein said human is less than 1 year old.

15. (original) The method of claim 6 herein said effective immunizing amount is between  $1 \times 10^5$  -  $1 \times 10^8$  plaque forming units (pfu).

16. (canceled)